Will PFE do rebounce ?Harmonic BAT pattern.
Just to practice my analysis.
The pattern will cancel if the price drop below 41.54.
PFE trade ideas
$PFE - Could see a bounce#PFE could see a double bottom bounce. If the price can break above $44.50 it could reach to $47 near term.
Target 1 - $45
Target 1 - $47
Target 2 - $51
——
Trade is done when it hit one of the target or stop loss is hit.
Disclaimer: Trading note. Not an investment advice.
PFE Call This week's selling (because of earnings) is a great chance to load up.
Might be some resistance around $48 but looks solid.
Pfizer 20% BounceTrading plan:
1. Wait until CM_Ultimater_MA_MFT_V2 indicates a reversal of secondary daily trend. This indication will be confirmed by change of the color of MA from red to green. Primary trend is still bearish until confirmed to be bullish.
2. CM_Williams_Vix_Fix at local daily bottom which can be seen as a confirmation of the reversal secondary bearish trend which started on December 29, 2022.
3. WT_LB is below oversold band which is also on daily timeframe is indicating a secondary trend reversal.
4. Resistance should a price ceiling of the bearish channel at $50-$52.
Implications:
1. Since CM_Ultimater_MA_MFT_V2 is lagging indicator there is a trade off between confirmation of the trend reversal and return rate of the trade. Therefore it could be prudent to start accumulating the position before we see a confirmation of the trend reversal by this MA.
2. This is post earnings period and Federal hike announcements/meetings have already passed. So volatility should be lower.
3. Of course this trading plan has worked out 100% in the last 8 times (of course there is an element of data mining) but trade should be done cautiously.
4. Stop loss would be if we start consolidating below $41-$40.5
Reckon it does not contract to the rationale I was trying to stick to:
- Identify a trend reversal (either primary of secondary on daily and weekly timeframes)
- Get into the position after considering different tools of confirmation and setting a stop loss.
- Ride the trend until there is a sign of trend reversal (either primary of secondary on daily and weekly timeframes) and try to get it confirmed.
- Close the position.
Please enjoy and if you have any further insights please share
Many thanks to the Community contributors (ChrisMoody and LazyBear). The tools they have assembled are of significant avail to all.
PFIZER (PFE) 6M Trading Analisys (TA)6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to $43, heading down to test the 100 days MA signal, at this moment there is a probability for the price to bounce up before continuing its way down to test the 100 MA signal, which is the optimistic approach, but remember "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy".
Today this ticker has a Volume of 5.297M with a Market Cap of 246B.
This Company PAYS DIVIDENDS TO SHAREHOLDERS
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Good Luck!
Gráfico de 6M, ( PFE ), al 6 de febrero de 2023, las señales en MACD se han estado moviendo constantemente hacia el NE, luego de cruzarse por debajo del histograma en julio de 2012; En julio de 2021, alcanzó su ATH (Mayor Precio Histórico); La señal RSI rebotó sobre 70 y ahora se dirige al SE para probar la señal de 50, luego de rebotar ahi en enero de 2020; El precio ha estado cayendo constantemente desde el ATH, de $60 a $43, bajando para probar la señal de 100 días MA, en este momento existe la probabilidad de que el precio rebote antes de continuar su camino hacia abajo para probar la señal de 100 MA, que es el enfoque optimista, pero recuerda: "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a tener razón nueve de cada diez veces. Descubrí que cuando el mercado está cayendo y compras fondos sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar".
Hoy este ticker tiene un Volumen de 5.297M con una Capitalización de Mercado de 246B.
Esta Empresa PAGA DIVIDENDOS A LOS ACCIONISTAS
Pfizer Inc. es una compañía biofarmacéutica global basada en la investigación. Se dedica al descubrimiento, desarrollo, fabricación, comercialización, venta y distribución de productos biofarmacéuticos en todo el mundo. La firma trabaja en mercados desarrollados y emergentes para promover el bienestar, la prevención, los tratamientos y las curas que desafían las enfermedades más temidas. La empresa fue fundada por Charles Pfizer Sr. y Charles Erhart en 1849 y tiene su sede en Nueva York, NY.
¡Buena suerte!
“I believe in analysis and not forecasting.” / "Creo en el análisis y no en el pronóstico".
REMEMBER : I am not a financial adviser nor is any content in this article presented as financial advice. The information provided in this blog post and any other posts that I make, and any accompanying material is for informational purposes only. It should not be considered financial or investment advice of any kind. One should consult with a financial or investment professional to determine what may be best for your individual needs. RECUERDE : No soy un asesor financiero y el contenido de este artículo no se presenta como asesoramiento financiero. La información provista en esta publicación de blog y cualquier otra publicación que haga y cualquier material que la acompaña es solo para fines informativos. No debe considerarse asesoramiento financiero o de inversión de ningún tipo. Se debe consultar con un profesional financiero o de inversiones para determinar qué es lo mejor para sus necesidades individuales.
PFE SqueezeMACD crossover, oversold RSI at 33, Strat Squeeze underway, 121 uptrend, touching the 9 EMA, if pokes through it will go to the 20 EMA, Red on D,Q; Green on 4H,W,M
$PFE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $PFE after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 100%.
PFERSI , MFI, And CCI Oversold.
Bounced around October lows.
Fib levels are ATH + 2009 lows
Stop loss 42$
Target area 48$ gap close..
This isn't your favorite tech stock that goes straight up so don't expect a rocket move.
Last 15% move from October lows took a month in a half out so grab some time
.
PFE into major SupportPfizer may provide a great risk to reward setup. Multi factor trade setup on pfizer likely sees a technical bounce. Keep in mind markets are weak.
earnings estimateas pandemic is slowering and chinese lockdown vix is going down stocks like pie healthcare can come down from their highs
Pharmaceutical Reversal?NYSE:PFE NYSE:ABBV will be on my watchlist next week.
Let's start with Pfizer first.
Pfizer has been down since mid of December 2022.
And now it is on interesting area (see on the chart)
In my view, area of $ 42.74 to $ 43.52 will be critical.
Next week Pivot Point will be at $ 44.24, if the price can stand above its weekly Pivot Point then a potential reversal may occur.
If we look at the weekly chart, EMA200 Weekly has been survived by the last downfall of PFE on October 2022.
MACD have shown a small bullish divergence.
Maybe an Earning Report can boost NYSE:PFE chart for next week.
Let's see.
$PFE - Oversold. Possible seller exhaustion#Pfizer has been oversold for some time. Today's gap down on UBS downgrade could be the seller exhaustion and potential bounce to come.
Target 1 - $46.5
Target 2 - $47.67
Target 3 - $51
Long term - $60
Risk - fall to $41.
——
Trade is done when it hit one of the target or stop loss is hit.
Disclaimer: Trading note. Not an investment advice.
$PFE: Interesting juncture here...Pfizer has a curious setup where both an uptrend or down trend could trigger next, depending on which extreme of last week's range is crossed first.
As per the chart, you can go long on a break of last week's high or short on a break of last week's low, with stops as depicted on chart. Targets may be subject to updates, if price action forms larger consolidation patterns in the direction of the trade and the initial entry isn't stopped. Odds of the trade working and making some progress in the next week are big if the trade is triggered, you could secure some gains by Friday close, if the target or the stop aren't hit, or just exit the trade altogether to revisit it next week, if continuation occurs.
Best of luck!
Ivan Labrie.
Potential 2-1-2 daily setupsPFE - failed 2u-1 on the daily, looking for more downside tomorrow. Put Trigger below 44.83. Put SL/Call trigger set at 45.32
JNJ - has a 2-1- on the daily. Feeling neutral but would prefer downside on this play. Call trigger above 169.62, Put trigger below 167.50. JNJ has earnings report tomorrow so be careful trading this one. (SL for call and put trigger is the other trigger)
HTHT - failed 2u-1 on the daily. Big gap to the downside on the daily. Only looking at puts below 48.06. SL above 48.95
PFE | Good Starter Position Entry | LONGPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE set back a good opportunityWe think the current setback provides a nice opportunity to buy some PFE with a nice dividend and decent ROE, for a move back into the low-to-mid fifties.
PFIZER could rise despite recent fallWe could see a rise in PFE's price in the next few weeks up to the $54.5 range, however, estimates for the Q4 22 earnings is lower then the previous quarter, if the price does not crash following the earnings, or perhaps if the earnings were positive, the price would likely rise, however it is best in this current state to only take small trades and play around with rather short swing trades.
Pfizer BullishThe Chart currently shows Bullish signal as per these indicators:
1. Bullish Falling Wedge Chart Pattern
2. Bullish Divergence ( RSI )
If the upper trendline is broken can expect further upside potential.
Pfizer in a bull flag.Pfizer - 30d expiry - We look to Buy a break of 48.31 (stop at 46.56)
Short term bias has turned positive.
Posted a bullish Flag formation.
A break of 48.26 is needed to confirm the outlook.
A break of the recent high at 48.26 should result in a further move higher.
Short term momentum is bullish.
This stock has seen good sales growth.
The bias is to break to the upside.
Our profit targets will be 52.69 and 53.69
Resistance: 48.00 / 49.70 / 52.00
Support: 46.70 / 46.00 / 44.70
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
push to resistance zone coming? 👀nice break past long trigger/trend resistance, if we can hold local trend supports a push to resistance zone is possible by end of year/early 2023
boost and follow for more 💛
PFE longWednesday morning, Pfizer unveiled its Q2 figures. They revealed that the pharmaceutical sector giant earned revenue of $19 billion, a robust 86% higher than in the same quarter of 2020. Much of this was, of course, due to the BNT162b2 coronavirus vaccine it's developed with Germany-based BioNTech. But even stripping out the vaccine's sales from the top line, the company still managed to grow revenue by 10% to $11.1 billion. On average, analysts tracking Pfizer stock were modeling $18.45 billion.
Quoted by the company as saying the quarter was "remarkable," CEO Albert Bourla signaled optimism for the coming years. He and his troops believe Pfizer will be able to hit a 6% compound annual revenue growth rate through 2025.
With that powerful quarter behind it, the confident Pfizer has upped its full-year guidance. It now expects $78 billion to $80 billion in revenue (previous estimate: $70.5 billion to $72.5 billion), and adjusted diluted per-share earnings of $3.95 to $4.05 (up from $3.55 to $3.65).
